Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1261-1266

  Lai, Jiun I ^a   Tzeng, Cheng Hwai ^a,b   Chen, Po Min ^a,b   Lin, Jen Kou ^a,b   Lin, Tzu Chen ^a,b   Chen, Wei Shone ^a,b   Jiang, Jeng Kae ^a,b   Wang, Huann Sheng ^a,b   Wang, Wei Shu ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUTAMINE; LYSINE; OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CHINESE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SENSITIVITY; ETHNIC DIFFERENCE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PREVALENCE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 67449085049     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01186.x     Document Type: Article

References (36)

1. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
2. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12.
3. Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 2007; 107: S56-71.
4. Luca AH, Hernandez J, Mountzios G et al. Excision repair cross complementation group1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 3855-9.
5. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-43.
6. Chang MS, Tzeng CH, Chen PM et al. ERCC1 codon 118 C>T polymorphism associated with ERCC1 expression and clinical outcome to FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2008 Dec 4 (Epub ahead of print).
7. McWilliams RR, Bamlet WR, Cunningham JM et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res 2008; 68: 4928-35.
8. Shore RE, Zeleniuch-Jacquotte A, Currie D et al. Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk. Int J Cancer 2008; 122: 2101-5.
9. Hoeijmakers JH, Egly JM, Vermeulen W. TFIIH: A key component in multiple DNA transaction. Curr Opin Gene Dev 1996; 6: 26-33.
10. Sung P, Bailly V, Weber C et al. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993; 365: 852-5.
11. Parshad R, Tarone RE, Price FM et al. Cytogenetic evidence for differences in DNA incision activity in xeroderma pigmentosum group A, C and D cells after X-irradiation during G2 phase. Mutat Res 1993; 294: 149-55.
12. Schaeffer L, Moncollin V, Roy R et al. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J 1994; 13: 2388-92.
13. Park DJ, Stoehlmacher J, Zhang W et al. Xeroderma pgmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8.
14. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenetics Genomics 2007; 17: 897-905.
15. Lainé JP, Vincent M, Marion B, Cathy B, Jean ME, Pierre B. Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair 2007; 6: 1264-70.
16. Spitz MR, Wu X, Wang Y et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354-7.
17. Lunn RM, Helzlsouer KJ, Parshad R et al. XPD polymorphisms: Effect on DNA repair proficiency. Carcinogenesis 2000; 21: 551-5.
18. Marsh S, Collie-Duguid ES, Li T et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999; 58: 310-12.
19. Liu CY, Chen PM, Chiou TJ et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112: 1932-40.
20. Jada SR, Lim R, Wong CI et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007; 98: 1461-7.
21. Kamikozuru H, Kuramochi H, Hayashi K et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 2008; 32: 1091-6.
22. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-54.
23. Yin J, Li J, Vogel U, Wang H. Polymorphisms of DNA repair genes: ERCC1 G19007A and ERCC2/XPD C22541A in a northeastern Chinese population. Biochem Genet 2005; 43: 543-8.
24. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-7.
25. Le Morvan V, Smith D, Laurand A et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 2007; 8: 1693-703.
26. Chen G, Gharib TG, Huang C-C et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 4: 304-13.
27. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-30.
28. Booton R, Ward T, Heighway J et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 2006; 106: 2421-7.
29. Allan JM, Smith AG, Wheatley K et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004; 104: 3872-7.
30. Zárate RN, Arias F, Bandres E, Cubedo E, Malumbres R, García-Foncillas J. Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J Gastroenterol 2006; 12: 6032-6.
31. Chang A, Parikh P, Thongprasert S et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1: 847-55.
32. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
33. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-91.
34. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
35. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050-6.
36. Grolleau F, Gamelin L, Boisdron-Celle M et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 2293-7.